Economy/Home · Economy

InvegtiLab Receives Phase 1 Clinical Trial Results from Australia for IVL3004 and IVL4002, Securing Safety and Pharmacokinetic Data

InvegtiLab announced that it has received the Clinical Study Report (CSR) for the Australian Phase 1 trials of IVL3004, a candidate for the treatment of alcohol and opioid dependence, and IVL4002, a candidate for the treatment of multiple sclerosis. The trials were conducted at Nucleus Network in A

Oseong Kwon
Staff Reporter
7 min read
InvegtiLab Receives Phase 1 Clinical Trial Results from Australia for IVL3004 and IVL4002, Securing Safety and Pharmacokinetic Data
CBC News

InvegtiLab announced that it has received the Clinical Study Report (CSR) for the Australian Phase 1 trials of IVL3004, a candidate for the treatment of alcohol and opioid dependence, and IVL4002, a candidate for the treatment of multiple sclerosis.

The trials were conducted at Nucleus Network in Australia to evaluate the safety, tolerability, and pharmacokinetic properties of the two candidates in healthy adults. The clinical trial period ran from September 11, 2024 to February 13, 2026, and 45 subjects were actually enrolled compared to a target of 40.

■ IVL3004: Most Adverse Reactions Mild, Injection Site Reactions Resolved Quickly

Safety and tolerability evaluations showed that most adverse reactions to IVL3004 were mild. A total of 146 treatment-emergent adverse events (TEAEs) were reported in 42 of 44 dosed subjects (95.5%). The main adverse drug reactions were injection site pain in 33 subjects (75.0%), nausea in 10 (22.7%), feeling depressed in 7 (15.9%), and fatigue and headache in 5 each (11.4%).

Notably, the average onset of injection site reactions in the IVL3004 groups was 1.5 to 2.5 days after administration, faster than the 4.9 days for the comparator drug Vivitrol. The average duration was also 4.3 to 4.7 days, shorter than the 17.2 days in the Vivitrol group, indicating relatively rapid resolution.

In pharmacokinetic evaluations, the maximum plasma concentration (Cmax) of the IVL3004 300mg and 380mg groups was 5.859 ng/mL and 8.256 ng/mL, respectively, lower than that of the Vivitrol group (14.226 ng/mL). Time to maximum concentration (Tmax) was 335.06 hours and 239.85 hours, respectively, longer than Vivitrol (48.1085 hours). The 300mg group maintained a mean naltrexone plasma concentration of approximately 1 ng/mL on day 29 after administration, confirming sustained drug exposure over a 28-day dosing interval.

■ IVL4002: Good Safety and Long-Release Characteristics Even After Single Administration

IVL4002, a treatment candidate for multiple sclerosis, showed good safety and tolerability after a single 50mg subcutaneous administration in healthy male subjects. There were no reports of severe treatment-emergent adverse reactions, serious adverse events, or deaths, and no trial discontinuations due to adverse reactions.

The Cmax of IVL4002 was measured at 0.760 ng/mL with a Tmax of 510.25 hours. Late-stage drug exposure between 240 and 672 hours after administration accounted for approximately 77% of total exposure up to 672 hours, and the plasma concentration on day 29 was observed at 0.432 ng/mL, supporting sustained drug exposure over a 28-day dosing interval and long-release characteristics.

■ Future Plans and Risk Factors

InvegtiLab stated that based on the safety, tolerability, and pharmacokinetic characteristics of IVL3004 and IVL4002 confirmed in these trials, it will review appropriate dosages and dosing regimens for subsequent development and continue future clinical development.

However, the company noted that the probability of a clinical trial drug ultimately receiving regulatory approval is statistically known to be around 10%, and explained that if future clinical trials or product approval processes yield results below expectations, it may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.